medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-12-75-81medsovet-2013Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАISHEMIC HEART DISEASEМЕХАНИЗМЫ ФОРМИРОВАНИЯ МИОКАРДИАЛЬНОГО ФИБРОЗА В НОРМЕ И ПРИ НЕКОТОРЫХ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ. МЕТОДЫ ЕГО ДИАГНОСТИКИMECHANISMS FOR THE FORMATION MYOCARDIAL FIBROSIS IN NORM AND IN CERTAIN CARDIOVASCULAR DISEASES, HOW TO DIAGNOSE ITМиклишанскаяС. В.MiklishanskayaS. V.

к.м.н.

PhD in medicine

МазурН. А.MazurN. A.

д.м.н., профессор

MD, Prof.

ШестаковаН. В.ShestakovaN. V.

к.м.н.  

PhD in medicine

Российская медицинская академия непрерывного последипломного образованияРоссияRussian Medical Academy of continuing post-graduate studiesRussian Federation2017021120170127581Copyright © Миклишанская С.В., Мазур Н.А., Шестакова Н.В., 20172017Миклишанская С.В., Мазур Н.А., Шестакова Н.В.Miklishanskaya S.V., Mazur N.A., Shestakova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2013

В обзоре изложены современные представления о механизмах формирования миокардиального фиброза, включая влияние гуморального и клеточного компонентов. Рассмотрены понятия внеклеточного матрикса и объема, их клиническое значение для прогрессирования сердечно-сосудистых заболеваний, представлены предпосылки для формирования новых подходов к лечению кардиальной патологии с учетом результатов определения внеклеточного объема при помощи МРТ.

 

 

 

 

The review summarizes current knowledge regarding the origins and role of myocardial fibrosis formation, including the effects of humoral and cellular components. The concepts of extracellular matrix and volume, their clinical significance for the progression of cardiovascular diseases, the background for the formation of new approaches for the treatment of cardiac pathology are considered, taking into account the results of determination of extracellular volume with the help of MRI.

фиброз миокардаколлагенвнеклеточный матриксвнеклеточный объеммагнитно-резонансная томографияcardiac fibrosiscollagenextracellular matrixextracellular volumecardiovascular magnetic resonance imagingReferencesГлотов М.Н., Мазур Н.А. Диастолическая функция левого желудочка у больных гипертонической болезнью: Обзор. Кардиология. 1994; 1-2:89-93.Глотов М.Н., Мазур Н.А. Диастолическая функция левого желудочка у больных гипертонической болезнью: Обзор. Кардиология. 1994; 1-2:89-93.Хежева Ф.М., Мазур Н.А. Сывороточные маркеры фиброза у больных артериальной гипертонией. Кардиология. 2006; 3:64-67.Хежева Ф.М., Мазур Н.А. Сывороточные маркеры фиброза у больных артериальной гипертонией. Кардиология. 2006; 3:64-67.Мазур Н.А. Органные поражения, нарушения метаболизма при артериальной гипертонии и влияние на них гипотензивной терапии. Тер. архив. 1995; 67: 3-5.Мазур Н.А. Органные поражения, нарушения метаболизма при артериальной гипертонии и влияние на них гипотензивной терапии. Тер. архив. 1995; 67: 3-5.Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart Failure With Preserved Ejection Fraction Molecular Pathways of the Aging Myocardium. Circ Res. 2014; 115: 97-107.Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart Failure With Preserved Ejection Fraction Molecular Pathways of the Aging Myocardium. Circ Res. 2014; 115: 97-107.Овчинников А.Г., Ожерельева М.Г., Агеев Ф.Т. Фиброз левого желудочка: патогенез, диагностика, лечение. Неотложная кардиология. 2015; №4: 11-26.Овчинников А.Г., Ожерельева М.Г., Агеев Ф.Т. Фиброз левого желудочка: патогенез, диагностика, лечение. Неотложная кардиология. 2015; №4: 11-26.Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015 66, NO. 8, 943-959.Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015 66, NO. 8, 943-959.Ivey M J, Tallquist MD. Defining the Cardiac Fibroblast. Circ J. 2016; 80: 2269–2276.Ivey M J, Tallquist MD. Defining the Cardiac Fibroblast. Circ J. 2016; 80: 2269–2276.Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010; 225: 631–637.Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010; 225: 631–637.Fu J, Srivastava D. Direct Reprogramming of Fibroblasts into Cardiomyocytes for Cardiac Regenerative Medicine. Circ J. 2015; 79: 245– 254.Fu J, Srivastava D. Direct Reprogramming of Fibroblasts into Cardiomyocytes for Cardiac Regenerative Medicine. Circ J. 2015; 79: 245– 254.Baum J, Duffy HS. Fibroblasts and myofibro-blasts: what are we talking about? J Cardiovasc Pharmacol. 2011; 57: 376–379.Baum J, Duffy HS. Fibroblasts and myofibro-blasts: what are we talking about? J Cardiovasc Pharmacol. 2011; 57: 376–379.Yong KW, Li Y, Huang G et al. Mechanoregulation of cardiac myofibroblast differentiation: implications for cardiac fibrosis and therapy. Am J Physiol Heart Circ Physiol. 2015; 309: H532–H542.Yong KW, Li Y, Huang G et al. Mechanoregulation of cardiac myofibroblast differentiation: implications for cardiac fibrosis and therapy. Am J Physiol Heart Circ Physiol. 2015; 309: H532–H542.Vasquez C, Benamer N, Morley GE. The Cardiac Fibroblast: Functional and Electrophysiological Considerations in Healthy and Diseased Hearts. J Cardiovasc Pharmacol. 2011; 57(4): 380–388.Vasquez C, Benamer N, Morley GE. The Cardiac Fibroblast: Functional and Electrophysiological Considerations in Healthy and Diseased Hearts. J Cardiovasc Pharmacol. 2011; 57(4): 380–388.Cartledge JE, Kane C, Dias P, et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res. 2015; 105: 260–70.Cartledge JE, Kane C, Dias P, et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc Res. 2015; 105: 260–70.Takeda N, Manabe I. Cellular Interplay between cardiomyocytes anda nonmyocytes in cardiac remodeling. Int J Inflam. 2011; 2011: 535241.Takeda N, Manabe I. Cellular Interplay between cardiomyocytes anda nonmyocytes in cardiac remodeling. Int J Inflam. 2011; 2011: 535241.Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–45.Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–45.Wynn Т.А. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199–210.Wynn Т.А. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199–210.Lawrie CH. Micro RNAs in Medicine. Wiley-Blackwell. 2013, p.720.Lawrie CH. Micro RNAs in Medicine. Wiley-Blackwell. 2013, p.720.Yilmaz A, Kindermann I, Kindermann M et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences incomplication rate and diagnostic performance. J Circulation. 2010; 122: 900-909.Yilmaz A, Kindermann I, Kindermann M et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences incomplication rate and diagnostic performance. J Circulation. 2010; 122: 900-909.Moon JC, Messroghli DR, Kellman P et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. Journal of Cardiovascular Magnetic Resonance. 2013, 15:92.Moon JC, Messroghli DR, Kellman P et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. Journal of Cardiovascular Magnetic Resonance. 2013, 15:92.Treibel TA, Zemrak F, Sado DM et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Journal of Cardio vascular Magnetic Resonance. 2015; 17:74-86.Treibel TA, Zemrak F, Sado DM et al. Extracellular volume quantification in isolated hypertension - changes at the detectable limits? Journal of Cardio vascular Magnetic Resonance. 2015; 17:74-86.Everett RJ, Stirrat CG, Semple SIR et al. Assessment of myocardial fibrosis with T1 mapping MRI. Clinical Radiology. 2016; 8: 768-778.Everett RJ, Stirrat CG, Semple SIR et al. Assessment of myocardial fibrosis with T1 mapping MRI. Clinical Radiology. 2016; 8: 768-778.Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013; 6: 672–683.Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013; 6: 672–683.Li Q, Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Comm. 2014; 452: 497–502.Li Q, Liu X, Wei J. Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. Biochem Biophys Res Comm. 2014; 452: 497–502.Wu J, Xia S, Kalionis B et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014; 2014: 615312.Wu J, Xia S, Kalionis B et al. The role of oxidative stress and inflammation in cardiovascular aging. BioMed Res Int. 2014; 2014: 615312.Boon RA, Iekushi K, Lechner S et al. Micro-RNA-34a regulates cardiac ageing and function. Nature. 2013; 495: 107–110.Boon RA, Iekushi K, Lechner S et al. Micro-RNA-34a regulates cardiac ageing and function. Nature. 2013; 495: 107–110.Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circulation: Cardiovascular Imaging 2017;10:e005619.Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circulation: Cardiovascular Imaging 2017;10:e005619.Travers JG, Kamal FA, Robbins J et al. Cardiac Fibro sis: The Fibroblast Awakens. Circ Res. 2016; 118: 1021–1040.Travers JG, Kamal FA, Robbins J et al. Cardiac Fibro sis: The Fibroblast Awakens. Circ Res. 2016; 118: 1021–1040.

The authors declare that there are no conflicts of interest present.